Meko Porter
Neurology · Bermuda Dunes, CANPI 1376701649
Payments from drug & device makers
Across 378 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$940
- Teva Pharmaceuticals USA, Inc.$898
- AbbVie$745
- Lundbeck LLC$629
- UCB, Inc.$522
- Neurelis, Inc.$430
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,30699%
- Education$821%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $940 |
| Teva Pharmaceuticals USA, Inc. | 71 | $898 |
| AbbVie | 46 | $745 |
| Lundbeck LLC | 24 | $629 |
| UCB, Inc. | 23 | $522 |
| Neurelis, Inc. | 19 | $430 |
| Biogen | 30 | $365 |
| Amgen | 13 | $292 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $239 |
| CSL Behring | 9 | $235 |
| Livanova USA, Inc. | 8 | $202 |
| Kyowa Kirin, Inc. | 9 | $192 |
| MDD US Operations, LLC | 12 | $192 |
| Sanofi | 8 | $190 |
| SK Life Science, Inc. | 7 | $186 |
| Pfizer | 7 | $134 |
| Neurocrine Biosciences, Inc. | 7 | $129 |
| Acadia Pharmaceuticals Inc | 5 | $125 |
| Amneal Pharmaceuticals LLC | 5 | $113 |
| Adamas Pharmaceuticals, Inc. | 5 | $94 |
| Biohaven Pharmaceuticals, Inc. | 4 | $89 |
| EMD Serono, Inc. | 3 | $82 |
| Eisai Inc. | 3 | $71 |
| Lilly USA, LLC | 3 | $58 |
| Aurinia Pharma U.S., Inc. | 2 | $48 |
| Scilex Pharmaceuticals Inc. | 2 | $41 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $37 |
| Upsher-smith Laboratories LLC | 1 | $22 |
| Acorda Therapeutics, Inc | 1 | $19 |
| Cala Health, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Abbott | 1 | $17 |
| Amylyx Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYEPTI$125
How this compares
$7,388 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 12 | $655,428 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $313,935 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 28 | $292,683 |
| NuplazidPimavanserin Tartrate | 51 | $266,342 |
| NourianzIstradefylline | 34 | $89,495 |
| AptiomEslicarbazepine Acetate | 23 | $49,752 |
| GocovriAmantadine Hcl | 14 | $46,758 |
| NeuproRotigotine | 38 | $31,186 |
| RytaryCarbidopa/Levodopa | 28 | $27,304 |
| QuliptaAtogepant | 21 | $23,378 |
| CambiaDiclofenac Potassium | 24 | $22,990 |
| Nurtec OdtRimegepant Sulfate | 15 | $21,733 |
| UbrelvyUbrogepant | 20 | $20,976 |
| FycompaPerampanel | 13 | $15,268 |
| ElyxybCelecoxib | 16 | $15,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $940 | $655,42812 claims |
| CSL BehringHizentra | $235 | $313,93512 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $239 | $292,68328 claims |
| Acadia Pharmaceuticals IncNuplazid | $125 | $266,34251 claims |
| Kyowa Kirin, Inc.Nourianz | $192 | $89,49534 claims |
| MDD US Operations, LLCGocovri | $192 | $46,75814 claims |
| AbbVieQulipta, Ubrelvy | $745 | $44,35441 claims |
| UCB, Inc.Neupro | $522 | $31,18638 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $113 | $28,73547 claims |
| PfizerNurtec Odt, Dilantin | $134 | $24,97243 claims |
| Eisai Inc.Fycompa | $71 | $15,26813 claims |
| Scilex Pharmaceuticals Inc.Elyxyb | $41 | $15,03316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,996 neurology providers in California.
Other neurology in Bermuda Dunes
- Timothy CloughesyLos Angeles$33.1M
- Jack FlorinFullerton$13M
- David KudrowSanta Monica$12.8M
- John Ravitsla Jolla$8.4M
- Perminder BhatiaFresno$8.3M
- Perry ShiehLos Angeles$8.2M
- Benjamin FrishbergCarlsbad$8.2M
- Bruce CreeSan Francisco$8M
- Lawrence RechtPalo Alto$6.6M
- Stanley PrusinerSan Francisco$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.